|
|
The Body Covers: The 9th Conference on Retroviruses and Opportunistic Infections
Conference Summaries: Day Two
Tuesday, February 26, 2002
- Antiretroviral Chemotherapy: Combination Therapy, Drug Resistance, and Treatment Interruption (Oral Abstract Session 13)
- Controversies in Antiretroviral Therapy (Symposium Session 21)
- Adherence to Therapy (Poster Session 73)
- Resistance to Antiretroviral Chemotherapeutic Agents (Poster Session 75)
- Switch Studies/Treatment of Lipodystrophy Syndromes (Poster Session 92)
- A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (Abstract 699-T)
Coverage by Andrew T. Pavia, M.D.
- A Randomised, Controlled, Open-Label Study of Revision of Antiretroviral Regimens Containing Stavudine (d4T) and/or a Protease Inhibitor (PI) to Zidovudine (ZDV)/Lamivudine (3TC)/Abacavir (ABC) to Prevent or Reverse Lipoatrophy: 48-Week Data (Abstract 700-T)
Coverage by Benjamin Young, M.D., Ph.D.
- Improvements in Lipoatrophy (LA) Are Observed After 24 Weeks When Stavudine (d4T) Is Replaced By Either Abacavir (ABC) or Zidovudine (ZDV) (Abstract 701-T)
Coverage by Benjamin Young, M.D., Ph.D.
- Atazanavir: A Once-Daily Protease Inhibitor With a Superior Lipid Profile: Results of Clinical Trials Beyond Week 48 (Abstract 706-T)
Coverage by Brian A. Boyle, M.D., J.D.
|
Advertisement
|
